Navigation Links
Shire plc: IFRS Results for the Year Ending December 31, 2007
Date:3/25/2008

Teva did not challenge two other patents relating to Combivir that expire in 2010 and 2016. The case is in its early stages.

ZEFFIX

Royalties from sales of ZEFFIX for the year to December 31, 2007 were US$41.0 million, an increase of 18% compared to the same period in 2006 (2006: US$34.8 million). The impact of foreign exchange movements has contributed 8% to the reported growth; excluding favourable foreign exchange movements there has been an increase of 10% compared to the same period in 2006.

Shire receives royalties from GSK on worldwide ZEFFIX sales. GSK's worldwide sales of ZEFFIX for the year to December 31, 2007 were US$341 million, an increase of 13% compared to the same period in 2006 (2006: US$301 million). This increase was mainly due to strong growth in the Chinese market and favourable foreign exchange rate movements.

Other

Other royalties are primarily in respect of REMINYL and REMINYL XL (known as RAZADYNE and RAZADYNE ER in the US), a product marketed worldwide (excluding the UK and the Republic of Ireland) by Janssen Pharmaceutical N.V. ("Janssen"), an affiliate of Johnson & Johnson. Shire has the exclusive marketing rights in the UK and the Republic of Ireland.

Barr and other companies have filed ANDA with the FDA for generic versions of RAZADYNE. Janssen and Synaptech Inc. ("Synaptech") have filed lawsuits against some of those ANDA filers. A trial was held during the week of May 21, 2007. No decision from the court has been issued to date.

Janssen and Synaptech filed lawsuits against Barr and Sandoz Inc. ("Sandoz") for infringement of their patent rights relating to RAZADYNE ER as a result of Barr and Sandoz filing ANDAs with the FDA for generic versions of RAZADYNE ER. No court dates have been set.

Cost of sales

For the year to December 31, 2007 the cost of sales was 14% of product sales (2006: 16%). The cost of sales for REPLAGAL in 2006 included a US$47.0 million (3% of product s
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
2. Shire plc: Correction Re Website
3. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
4. Shire Engages Palio
5. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
6. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
7. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
8. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
9. Shire plc: Board Changes
10. David Mott Appointed Non Executive Director at Shire
11. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 Mathematic studies at the Program for ... funded by the Jeffrey Epstein VI Foundation , have ... visually identified for elimination. These aggressive cells are the driver ... a topological map of what to look for when examining ... while tumor cells can be extracted from biopsy, it,s very ...
(Date:8/21/2014)... Sofia, Bulgaria (PRWEB) August 21, 2014 ... was released today by Ontotext . Now ... and semantic analysis of structured and unstructured data is ... of the cost of enterprise technology. Organizations that do ... approaches for data management can use S4 since there ...
(Date:8/20/2014)... licensed to biotechnology firms has revealed early bottlenecks ... roadblocks, the researchers suggest that better communication of ... lead to faster commercialization down the road. , ... in university laboratories and licensed to biotechnology firms. ... have a high failure rate. But a new ...
(Date:8/20/2014)... Mass. , Aug. 20, 2014  Decision Resources Group finds ... , Russia , India ... $1.6 billion in 2013, roughly equal to the size of ... however, the BRIC market will experience much faster growth as a ... aging population. Other key findings from Decision Resources Group,s ...
Breaking Biology Technology:Science Power Jeffrey Epstein and Harvard University Fund Project to Visually Stop Tumor Growth 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 3
... ROCKVILLE, Md., Jan. 9, 2012  Neuralstem, Inc. (NYSE Amex: ... Richard Garr will present at the 2012 Biotech Showcase ... Garr will serve on the Therapeutic Focus Panel entitled, ... Alliance for Regenerative Medicine (ARM) Insight Track. Garr will ...
... WOBURN, Mass., Jan. 9, 2012 Advanstar|CBI recently announced ... and Access Programs. The Forum takes place March 6-7, ... includes leading experts from Eli Lilly, Genentech, AstraZeneca, Shire ... Patient Assistance Pavilion participant Needy Meds recently interviewed PAP,s ...
... Jan. 9, 2012   Veracyte, Inc ., a ... molecular cytology, today announced that Palmetto GBA, a ... coverage for the company,s Afirma Gene Expression Classifier ... that Veracyte,s genomic test is now accessible to ...
Cached Biology Technology:Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase 2Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase 3Veracyte Announces Medicare Coverage for Its Afirma® Gene Expression Classifier for Improved Thyroid Nodule Diagnosis 2Veracyte Announces Medicare Coverage for Its Afirma® Gene Expression Classifier for Improved Thyroid Nodule Diagnosis 3
(Date:8/21/2014)... researchers at Louisiana Tech University has developed ... 3D printers and materials to fabricate custom ... chemotherapeutic compounds for targeted drug delivery. , ... research faculty from Louisiana Tech,s biomedical engineering ... filament extruders that can make medical-quality 3D ...
(Date:8/20/2014)... pregnant teenagers in Rochester, NY, nearly half engaged in ... cornstarch, vacuum dust, baby powder and soap, and other ... such teens had significantly lower iron levels as compared ... Pregnant teens, regardless of pica, are at higher risk ... and anemia. Low iron in pregnant teens raises the ...
(Date:8/20/2014)... are visible in in this image of the Para ... these were most likely intentionally set in order to ... forest or stand of trees where the land is ... include conversion of forestland to farms, ranches, or urban ... green of the Amazon Rainforest in the middle of ...
Breaking Biology News(10 mins):Louisiana Tech University researchers use 3D printers to create custom medical implants 2Louisiana Tech University researchers use 3D printers to create custom medical implants 3Pica in pregnant teens linked to low iron 2
... trees that once characterized expansive tracts of tropical rainforest ... Just how big a role these winged gardeners play ... at Chicago and several Latin American universities are about ... laboratory in Mexico's gulf coast state of Veracruz. , ...
... plants such as corn, soybeans and sunflowers into fuel ... biodiesel generates, according to a new Cornell University and ... energy benefit to using plant biomass for liquid fuel," ... Cornell. "These strategies are not sustainable." , Pimentel and ...
... structural details of a family of mysterious objects called ... of bacteria. The discovery was published Aug. 5 in ... at how microcompartments are built, and what the pieces ... chemistry and biochemistry, and a member of the UCLA-DOE ...
Cached Biology News:Birds and bats sow tropical seeds 2Birds and bats sow tropical seeds 3Ethanol and biodiesel from crops not worth the energy 2New discovery blurs distinction between human cells and those of bacteria 2New discovery blurs distinction between human cells and those of bacteria 3
synphilin-1 (V-19)...
... contains the basic components required for the ... and recombinant canine Monocyte Chemotactic Protein 1 ... Each kit contains sufficient materials to run ... that the following conditions are met:2 ...
... MaV203 Competent Yeast Cells are designed for ... 1). S. cerevisiae strain MaV203 contains deletions ... for use with GAL4-based two-hybrid systems. The ... for selection of ProQuest bait and prey ...
Anti-Cullin-1 Host: rabbit polyclonal Species Reactivity: human, mouse Applications: IHC(P), WB, IP Storage: 4C...
Biology Products: